Analysis of the morbidity of breast cancer in Ukraine and the city of Kyiv

Abstract

One of the main causes of mortality worldwide is malignant neoplasms, and in Ukraine, breast cancer ranks first among all cancer diseases and mortality among women. With the help of official epidemiological data, it is possible to estimate the level and forecast the costs of the prevention and treatment of breast cancer in women. The purpose of the study was to analyze epidemiological indicators of breast cancer incidence and mortality among the female population in Ukraine and the city of Kyiv. The study used data on the incidence and mortality from breast cancer in women of the National Cancer Registry of Ukraine for 2011–2021. Analytical-comparative, epidemiological, graphic, and mathematical-statistical methods were used. The results of the analysis of epidemiological indicators showed that the largest number of sick women was registered in 2012 – 17,746, and the smallest in 2020 – 12,736. The highest growth rate of the chain coefficient of decrease/increase in the incidence and mortality rate of breast cancer in women was in 2015 – 23% and 8%, respectively. The lowest number of registered cases of breast cancer for 2016–2020 in Ukraine is observed in the Western region, and the largest in the Northern region. The highest mortality rate was recorded in women in the city of Kyiv and in Ukraine as a whole from breast cancer in 2012 (18.2 and 16.9 per 100,000 population, respectively). In general, the mortality trend in the city of Kyiv is higher than in Ukraine. The results of the analysis showed that breast cancer is most often detected for the first time at the I–II stage of the disease. The largest number of such patients was found in Ukraine in 2015 – 78.6% of the total number of cases. Taking into account the analyzed epidemiological data on the incidence and mortality of women from breast cancer in Ukraine and the city of Kyiv, it is necessary to conduct social programs for early screening of breast cancer at the state level and provide such patients with effective anticancer drugs at all stages of treatment.